Pfizer Confirms Paxlovid’s High Efficacy And Reassures On Omicron

89% Relative Risk Reduction Confirmed

 
• By Andrew McConaghie

While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.

Pfizer new logo building
Pfizer's Paxlovid could have a big impact on COVID-19 hospitalizations and deaths once authorized around the world • Source: Alamy

More from Business

More from Scrip